Portfolio | OBIO Accelerates Clinical Development and Commercialization of Metabolically Enhanced CAR-T Therapy
Leman Biotech
Developer of Novel Tumor Immunotherapy Drugs
Click the blue words to follow us.
Brief news
Recently, Obio Technology (Shanghai) Corp., Ltd. ("Obio Technology") announced a strategic collaboration with Leman Biotech Co., Ltd. ("Leman Bio") to jointly advance the development and commercialization of metabolism-enhanced CAR-T therapies. At the project kick-off meeting, representatives from both parties engaged in in-depth discussions regarding the pharmaceutical development of metabolism-enhanced CAR-T, IND submissions in China and the U.S., and the subsequent advancement of registrational clinical trials, accelerating the progress toward registrational clinical trials and commercialization of metabolism-enhanced CAR-T therapies.
The key areas of this cooperation involveMetabolism-Enhanced CD19 CAR-T Cell Therapy, which is currently conducting IIT clinical research at the First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) and the First Affiliated Hospital of Zhejiang University School of Medicine. The project has successfully completed the enrollment and treatment of more than 20 adult patients with relapsed/refractory leukemia/lymphoma, all achieving complete remission (CR) and being discharged. Both parties are committed to expediting the registration clinical trials and commercial approval of the metabolism-enhanced CD19 CAR-T cell drug, allowing safe, effective, and accessible immune-metabolic reprogramming drugs to benefit a wide range of cancer patients sooner.
Obio Technology (Shanghai) Corp., Ltd. has accumulated profound experience and innovation capabilities, relying on its ownT-flash Rapid Production Process Platform, paving the way for Leman Biotech's cell therapy drugs to successfully advance towards commercialization. The T-flash rapid production process platform can effectively reduce costs, shorten delivery times, decrease Vein-to-vein time, and allow for better control of the product and process, achieving better efficacy with a lower dose.
Obio Technology (Shanghai) Corp., Ltd. can provide
One-stop Solution for Immune Cell and Stem Cell Therapy
——The above content is from: Obio Technology
Previous Recommendations
➡️ Shengshan Capital Leads Over 100 Million Yuan B-Round Financing for HuiXiang Technology
➡️ Shengshan Capital Leads Nearly 100 Million Yuan Series A Financing for Hanhong Technology
Shengshan Capital
Shengshan Capital was founded in 2014 and focuses on equity investment in life sciences and healthcare. The company's founders and investment research team have years of experience in medical expertise, industry background, and capital operations. With the characteristics of "technology-driven, clinically-oriented, industrial integration, and value investing," they deeply focus on leading companies in the biotechnology, innovative drug, and digital healthcare sectors, acting as long-term enablers for businesses. Invested projects include: Cambridge Technology (603083.SH), OLED (688378.SH), Viva Biotech (1873.HK), Sunshine Nuogene (688621.SH), Obio Technology (688238.SH), Kangfeng Biotech (6922.HK), Meizhong Jiayhe (2453.HK), Yikon Genomics, Geneplus-Beijing, Eureka Med, Star Array, Jiangfeng Biotech, Peak Health, Genhouse Pharma, Changjin Biotech, HanHong Tech, Huxiang Tech, etc.